분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-08-15 01:07:28 , Hit : 1507
 Sovaldi forces Incivek off the hep C market as Vertex calls it quits

Topics:Sales and Marketing

August 13, 2014 | By Carly Helfand

Vertex is discontinuing sales of Incivek.--Courtesy of Vertex Pharmaceuticals
Bye-bye, Incivek. Just three years after nabbing the "fastest drug launch ever" award, maker Vertex is discontinuing the hepatitis C med on withering demand. For that, the Cambridge-based company has Gilead Sciences--owner of the new fastest drug launch ever--to thank.

According to a Monday letter to healthcare providers, Vertex ($VRTX) will put the kibosh on sales and distribution of the one-time blockbuster by October 16. The company said it made the decision in view of diminishing market share and "available alternative treatments"--read: Sovaldi.

The revolutionary Gilead ($GILD) drug, which cures 90% of patients after a 12-week treatment course, has taken a serious toll on Incivek sales. In 2012 and 2013, Incivek drove the majority of the company's revenues. But as of last quarter, Incivek revenues made up just 8% of the company's top line haul; in the first 6 months of this year, sales of the treatment crashed to $13.2 million--a 96% drop from the $361.4 million Incivek generated in the same period last year.

The $84,000-per-regimen Sovaldi, on the other hand, has raked in since its launch despite payer pushback on its high price tag. The drug posted a record-breaking $2.27 billion in Q1, following up with a $3.5 billion showing that crushed analyst estimates.

Vertex's move doesn't exactly come as a surprise. Earlier this year, the company announced it would be bowing out of hep C R&D, outlicensing its remaining drug for the condition, VX-135

So what's next for Vertex? The Massachusetts company will keep doubling down on Kalydeco, a wonder drug for cystic fibrosis. Vertex is working on expanding the orphan drug's label, and those efforts have so far proved fruitful. Most recently, the drugmaker widened its patient pool by about 250 with an EMA approval for 8 non-G551D gating mutatio

http://www.fiercepharma.com/story/sovaldi-forces-incivek-hep-c-market-vertex-calls-it-quits/2014-08-13?utm_medium=nl&utm_source=internal







947   Gilead Licenses Hepatitis Therapy in India Amid Price Criticism  이성욱 2014/09/17 1703
946   자신의 유전체를 해체하고 재조립하는 단일 세포  이성욱 2014/09/15 1447
945   STAP세포논문철회에서 새롭게 밝혀진 사실들  이성욱 2014/09/15 1304
944   질 속의 미생물(vaginal microbe)이 생성하는 새로운 항생제  이성욱 2014/09/15 1479
943   자연계의 항생제 공장에서 스위치 역할을 하는 소분자 물질  이성욱 2014/09/04 1945
942   Daclatasvir (Daklinza) for Chronic Hepatitis C Cleared in EU  이성욱 2014/08/29 2133
941   소아암 촉진 유전자 Lin28b 규명  이성욱 2014/08/18 1459
940   바이러스를 저지시키는 방법  이성욱 2014/08/15 1649
  Sovaldi forces Incivek off the hep C market as Vertex calls it quits  이성욱 2014/08/15 1507
938   Genetically 'edited' fruit could soon hit supermarket shelves  이성욱 2014/08/15 1324
937   암 연구를 위한 새로운 유전자 편집 기술  이성욱 2014/08/11 1448
936   New Guide RNAs for CRISPR Can Double the Targetable Genome  이성욱 2014/08/09 2140
935   일본의 뇌과학자 요시키 사사이의 죽음  이성욱 2014/08/08 1766
934   Roche says to buy Danish Santaris for up to $450 million  이성욱 2014/08/06 1300
933   뇌종양이 남성에서 더 흔한 이유?  이성욱 2014/08/06 1653
932   서아프리카의 에볼라 사태, 전 지구적 재앙으로 이어질 수 있을까?  이성욱 2014/08/06 1531
931   가장 중요한 감시자 p53의 새로운 기능!  이성욱 2014/08/05 1420
930   HIV를 죽게하는 강제적인 돌연변이  이성욱 2014/08/04 1460
929   「신약승인을 위한 임상시험 데이터」, 공개해야 하나?  이성욱 2014/08/01 1456
928   miRNA를 이용한 계통발생 분석의 문제점  이성욱 2014/08/01 1667

[이전 10개] [1]..[11][12][13][14][15][16] 17 [18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN